-

Shareholder Alert: Robbins LLP Announces ProAssurance Corporation (PRA) Accused of Misleading Shareholders

SAN DIEGO & BIRMINGHAM, Ala.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of ProAssurance Corporation (NYSE: PRA) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between April 26, 2019 and May 7, 2020. ProAssurance is one of the largest medical insurance providers in the U.S.

If you suffered a loss as a result of ProAssurance's misconduct, click here.

ProAssurance Corporation (PRA) Accused of Misleading Shareholders

According to the complaint, ProAssurance’s most important division is its Specialty Property and Casualty segment (“Specialty P&C”), which has accounted for at least 60% of its gross premiums written since 2015. In 2016, ProAssurance underwrote a very large specialty policy for one large healthcare provider customer, assuring investors that its reserves were "adequate" and "appropriate," and reflecting a "conservative view" when established. Despite assurances, on January 22, 2020, ProAssurance revealed that it was estimating a $37 million adverse development in its Specialty P&C loss reserves for fourth quarter 2019 due to a deteriorating loss experience related to the large account underwritten in 2016. Then one month later, ProAssurance revealed that the adverse development from the 2016 underwritten account was actually $51.5 million rather than the initial estimate of $37 million. Finally, on May 8, 2020, ProAssurance disclosed that its large healthcare client would likely not renew its policy and instead would exercise an option for tail coverage that would result in an additional $50 million in losses, for an aggregate of over $100 million in losses on a single account. Following all of these disclosures, ProAssuranc's stock fell nearly 57% from a closing price of $37 per share on January 22, 2020, to close at $15.95 per share on May 8, 2020.

ProAssurance Corporation (PRA) Shareholders Have Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action on behalf of ProAssurance settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:PRA

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom